• Explore /
  • Poster
  • / Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069).

Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069).

Abstract Poster

Authors

null

F. Stephen Hodi

Dana-Farber Cancer Institute, Boston, MA

F. Stephen Hodi , Michael Andrew Postow , Jason Alan Chesney , Anna C. Pavlick , Caroline Robert , Kenneth F. Grossmann , David F. McDermott , Gerald P Linette , Nicolas Meyer , Jeffrey K. Giguere , Sanjiv Agarwala , Montaser F. Shaheen , Marc S. Ernstoff , David R. Minor , April K. Salama , Matthew H. Taylor , Patrick Alexander Ott , Joel Jiang , Paul Gagnier , Jedd D. Wolchok

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT01927419

Citation

J Clin Oncol 34, 2016 (suppl; abstr 9518)

DOI

10.1200/JCO.2016.34.15_suppl.9518

Abstract #

9518

Poster Bd #

123

Abstract Disclosures

Similar Posters

First Author: Geoffrey Thomas Gibney

Poster

2020 ASCO-SITC Clinical Immuno-Oncology Symposium

Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.

Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.

First Author: Karim Welaya

First Author: Jeffrey S. Weber

First Author: David Hogg